Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Affinity Investment Advisors LLC

Affinity Investment Advisors LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 6.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,170 shares of the medical research company’s stock after acquiring an additional 332 shares during the quarter. Amgen accounts for approximately 1.1% of Affinity Investment Advisors LLC’s investment portfolio, making the stock its 28th biggest position. Affinity Investment Advisors LLC’s holdings in Amgen were worth $1,666,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of AMGN. Keynote Financial Services LLC raised its stake in Amgen by 0.6% during the second quarter. Keynote Financial Services LLC now owns 4,898 shares of the medical research company’s stock worth $1,530,000 after purchasing an additional 30 shares during the period. Ascent Group LLC raised its position in shares of Amgen by 0.3% in the 2nd quarter. Ascent Group LLC now owns 10,949 shares of the medical research company’s stock worth $3,421,000 after buying an additional 31 shares during the period. RFP Financial Group LLC boosted its holdings in Amgen by 17.1% in the first quarter. RFP Financial Group LLC now owns 219 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 32 shares during the last quarter. Hofer & Associates. Inc grew its position in Amgen by 0.5% during the second quarter. Hofer & Associates. Inc now owns 6,477 shares of the medical research company’s stock valued at $2,024,000 after acquiring an additional 32 shares during the period. Finally, Cadinha & Co. LLC increased its stake in Amgen by 0.6% during the third quarter. Cadinha & Co. LLC now owns 5,209 shares of the medical research company’s stock worth $1,678,000 after acquiring an additional 32 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. UBS Group reduced their target price on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday. Sanford C. Bernstein started coverage on shares of Amgen in a research report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target for the company. Barclays raised their price objective on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Finally, Robert W. Baird reaffirmed an “underperform” rating and issued a $215.00 target price on shares of Amgen in a research report on Wednesday, September 25th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $333.50.

Amgen Stock Performance

Shares of AMGN stock opened at $319.22 on Friday. The company has a market cap of $171.53 billion, a P/E ratio of 40.87, a PEG ratio of 2.84 and a beta of 0.61. The business has a 50 day moving average of $324.47 and a two-hundred day moving average of $315.19. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 181.58% and a net margin of 13.00%. The business’s revenue was up 23.2% on a year-over-year basis. During the same quarter last year, the business posted $4.96 EPS. As a group, analysts anticipate that Amgen Inc. will post 19.48 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 2.82%. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.